Article
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Clinical pharmacology and therapeutics - 1 Oct 2001
Laine K, Tybring G, Härtter S, Andersson K, Svensson J O, Widén J, Bertilsson L
Abstract excerpt
BACKGROUND: The ultrarapid metabolizer phenotype of the cytochrome P4502D6 (CYP2D6) enzyme has been considered a relevant cause of nonresponse to antidepressant drug therapy. Prescribing high doses of antidepressants to such patients leads to high concentrations of potentially toxic metabolites and an increased risk for adverse reactions. Normalization of the metabolic status of ultrarapid metabolizers by...
Topics
- Adult
- Antidepressive Agents, Tricyclic
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 CYP2D6 Inhibitors
- Debrisoquin
- Drug Combinations
- Drug Interactions
- Enzyme Inhibitors
- Female
- Humans
- Hypotension, Orthostatic
- Male
- Middle Aged